32 results about "Cellular biomarkers" patented technology

Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.

In this invention, a biomarker discovery method has been developed using specific biotin-labeled oligonucleotide ligands and magnetic streptavidin beads. In one embodiment, the oligonucleotide ligands are firstly generated by whole-cell based SELEX technique. Such ligands can recognize target cells with high affinity and specificity and can distinguish cells that are closely related to target cells even in patient samples. The targets of these oligonucleotide ligands are significant biomarkers for certain cells. These important biomarkers can be captured by forming complexes with biotin-labeled oligonucleotide ligands and collecting the complexes using magnetic streptavidin beads, whereupon the captured biomarkers are analyzed to identify the biomarkers. Analysis of biomarkers include HPLC-Mass Spectroscopy analysis, polyacrylamide gel electrophoresis, flow cytometry, and the like. The identified biomarkers can be used for pathological diagnosis and therapeutic applications. Using the disclosed methods, highly specific biomarkers of any kinds of cells, in particular cancer cells, can easily be identified without prior knowledge of the existence of such biomarkers.

The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and / or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and / or survival of cancer stem cells in a subject in need thereof.

The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

A new sensitive cell biomarker of solid tumors and viral infection is identified in blood. This biomarker can be used to determine presence of carcinomas, sarcomas, and viruses, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.

Methods for identifying active angiogenesis and vasculopathy are described. More particularly, the present disclosure relates to cellular biomarkers, and to methods of screening cellular biomarkers for identifying active angiogenesis.

A new sensitive cell biomarker of solid tumors is identified in blood. This biomarker can be used to determine presence of solid tumors, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.

A new sensitive cell biomarker of solid tumors is identified in blood. This biomarker can be used to determine presence of carcinomas, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.

Provided herein is a magnetic apparatus for collecting superparamagnetic particles from a subject. The superparamagnetic particles are previously injected into the subject and have ligands bound thereto that are specific for one or more non-cell biomarkers. In one embodiment, the superparamagnetic particles are injected into and retrieved from a cavity such as a joint cavity. These compositions and methods allow for the sequestration and removal of inflammatory mediators, as both a diagnostic of the local immune response and a therapeutic that can reduce inflammation in the local disease environment.

The present invention discloses microfluidic devices and methods for the enrichment and detection of rare cells such as circulating tumor cells (CTCs) and other biomarkers including proteins and DNA / RNA from biological fluid samples. The device improves upon existing microfluidic devices by optimizing the microfluidic design of its cell capture chamber at the micron level to mimic natural smooth surfaces such as those of the ocean floor or river bed. The smooth surface is characterized by creating a gentle environment and enhancing sample mixing to improve sustained cell-antibody contact and capture of rare cells while reducing shear-induced cell damage. The cell capture module is coated with a cell capture ligand. A second optional module binds acellular biomarkers with high sensitivity, enriching acellular biomarkers 100 to 1000-fold while enriching cellular biomarkers.

The invention relates to the field of biotechnology, specifically to a specific biomarker of an initial CD4<+>T cell and / or a regulatory T cell differentiated from the initial CD4<+>T cell and / or maturity state and function. The invention provides application of long non-coding RNA (namely lnc-Smad3) as shown in the SEQ ID NO:1 or complementary or homologous RNA sequence as a biomarker for identifying the initial CD<+>T cell and / or a regulatory T cell differentiated from the initial CD4<+>T cell, application of a reagent for detecting RNA sequence level in the preparation of a kit for identifying the an initial CD4<+>T cell and / or a regulatory T cell differentiated from the initial CD4<+>T cell, and a corresponding kit and a method thereof. The invention provides a convenient and effective specific biomarker and a method for clinical and scientific research and identification of an initial CD4<+>T cell and / or a regulatory T cell differentiated from the initial CD4<+>T cell and maturity degree thereof. The specific biomarker has a wide application prospect.